首页 | 本学科首页   官方微博 | 高级检索  
按 检索        


Gadoxetate-enhanced versus diffusion-weighted MRI for fused Ga-68-DOTANOC PET/MRI in patients with neuroendocrine tumours of the upper abdomen
Authors:Marius E Mayerhoefer  Ahmed Ba-Ssalamah  Michael Weber  Markus Mitterhauser  Harald Eidherr  Wolfgang Wadsak  Markus Raderer  Siegfried Trattnig  Andreas Herneth  Georgios Karanikas
Institution:1. Department of Radiology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria
5. PET/CT Center, Departments of Radiology and Nuclear Medicine, Medical University of Vienna/Vienna General Hospital, Waehringer Guertel 18-20, 1090, Vienna, Austria
2. Department of Nuclear Medicine, Radiochemistry and Biomarker Development Unit, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria
3. Department of Internal Medicine I, Division of Oncology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria
4. Department of Nuclear Medicine, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria
Abstract:

Objectives

To compare fused gadoxetate-enhanced Ga-68-DOTANOC PET/MRI and Ga-68-DOTANOC PET/DWI (diffusion-weighted imaging) for the assessment of abdominal neuroendocrine tumours (NETs).

Methods

Eighteen patients with suspected or histologically proven NETs of the abdomen were enrolled in this retrospective study. All patients underwent Ga-68-DOTANOC PET/CT for a primary search, staging, or restaging, and received an additional MRI, including dynamic gadoxetate-enhanced T1-weighted sequences and DWI (b-values 50, 300 and 600). Co-registered gadoxetate-enhanced PET/MRI and PET/DWI were separately analysed for NET lesions by a nuclear medicine physician and a radiologist in consensus. Sensitivity and specificity were calculated on a per-region, per-organ and per-patient basis.

Results

Eighty-seven out of 684 anatomical regions, and 23 out of 270 organs, were NET-positive in 14 out of 18 patients. Region-based sensitivities and specificities were 97.7 % and 99.7 % for gadoxetate-enhanced PET/MRI and 98.9 % and 99.7 % for PET/DWI. Organ-based sensitivities and specificities were 91.3 % and 99.6 % for gadoxetate-enhanced PET/MRI and 95.7 % and 99.6 % for PET/DWI. Finally, patient-based sensitivities and specificities were 100 % and 100 % for gadoxetate-enhanced PET/MRI and 100 % and 75 % for PET/DWI. Sensitivities and specificities of the two methods did not differ significantly.

Conclusions

Gadoxetate-enhanced Ga-68-DOTANOC PET/MRI and Ga-68-DOTANOC PET/DWI are equally useful for the assessment of abdominal NETs.

Key Points

? Positron emission tomography and magnetic resonance imaging can both assess neuroendocrine tumours. ? Fusion of PET/MR imaging provides helpful information. ? Gadoxetate-enhanced Ga-68-DOTANOC PET/MRI and Ga-68-DOTANOC PET/DWI assess neuroendocrine tumours equally well. ? PET/DWI is inherently simpler than gadoxetate-enhanced PET/MRI. ? Only benign hepatic lesions pose a potential diagnostic dilemma for PET/DWI.
Keywords:
本文献已被 SpringerLink 等数据库收录！
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号